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1CANCER IN IOWA
2012
A Focus on Lung Cancer
STATE HEALTH REGISTRY OF IOWA
2In 2012, a projected 6,400 Iowans will die from cancer,  
17 times the number caused by auto fatalities. Cancer and  
heart disease are the leading causes of death in Iowa.  
These projections are based upon mortality data the State  
Health Registry of Iowa receives from the Iowa Department  
of Public Health. The Registry has been recording the  
occurrence of cancer in Iowa since 1973, and is one of fourteen 
population-based registries and three supplementary registries 
nationwide providing data to the National Cancer Institute (NCI). 
With 2012 Cancer in Iowa the Registry makes a general report  
to the public on the status of cancer. 
This report will focus on:
 * a description of the Registry and its goals;
 * cancer projections for 2012;
 * a special section on lung cancer;
 * brief summaries of recent/ongoing research projects;
 * a selected list of publications from 2011.
3THE STATE HEALTH REGISTRY OF IOWA  
Cancer is a reportable disease  
as stated in the Iowa Administrative 
Code. Cancer data are collected by  
the State Health Registry of Iowa, 
located at The University of Iowa in  
the College of Public Health’s 
Department of Epidemiology. The  
staff includes more than 50 people.  
Half of them, situated throughout the 
state, regularly visit hospitals, clinics, 
and medical laboratories in Iowa  
and neighboring states to collect  
cancer data. A follow-up program tracks 
more than 99 percent of the cancer 
survivors diagnosed since 1973. This 
program provides regular updates for 
follow-up and survival. The Registry 
maintains the confidentiality of the 
patients, physicians, and hospitals 
providing data.
 In 2012 data will be collected  
on a projected 17,500 new cancers  
among Iowa residents. In situ cases 
of bladder cancer are included in the 
projections for bladder cancer, to be 
in agreement with the definition of 
reportable cases of the Surveillance, 
Epidemiology, and End Results (SEER) 
Program of the NCI. 
 Since 1973 the Iowa Registry 
has been funded by the SEER Program 
of the NCI. Iowa represents rural and 
Midwestern populations and provides 
data included in many NCI publications. 
Beginning in 1990 about 5-10 percent  
of the Registry’s annual operating 
budget has been provided by the 
state of Iowa. Beginning in 2003, 
the University of Iowa has also been 
providing cost-sharing funds. The 
Registry also receives funding through 
grants and contracts with university, 
state, and national researchers 
investigating cancer-related topics.
The goals of the Registry are to:
•  assemble and report measurements of cancer incidence, survival and mortality 
among Iowans;
•  provide information on changes over time in the extent of disease at diagnosis, 
therapy, and patient survival;
•  promote and conduct studies designed to identify factors relating to cancer 
etiology, prevention and control; 
•  respond to requests from individuals and organizations in the state of Iowa for 
cancer data and analyses; 
•  provide data and expertise for cancer research activities and educational 
opportunities. 
The State Health 
Registry of Iowa 
is the best 
statewide resource 
for determining 
the burden of 
cancer on the Iowa 
population and 
assessing trends in 
the occurrence of 
cancer over time. 
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CANCER PROjECTIONS FOR 2012
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Projected Number of Cancer Deaths in Iowa for 2012
Projected Number of New Cancers in Iowa for 2012
4
New Cancers in Females
Type                 # of Cancers % of Total
Breast 2250 26.5
Lung 1060 12.5
Colon & Rectum 850 10.0
Uterus 600 7.1
Non-Hodgkin Lymphoma 370 4.3
Thyroid 350 4.1
Skin Melanoma 340 4.0
Leukemia 250 2.9
Ovary 240 2.8
Kidney & Renal Pelvis 230 2.7
All Others 1960 23.1
Total 8500
New Cancers in Males
Type                 # of Cancers % of Total
Prostate 2250 25.0
Lung 1300 14.4
Colon & Rectum 850 9.4
Bladder (invasive  640 7.1 
    and noninvasive) 
Non-Hodgkin Lymphoma 420 4.7
Skin Melanoma 420 4.7
Kidney & Renal Pelvis 390 4.3
Leukemia 270 3.0
Oral Cavity 250 2.8
Pancreas 240 2.7
All Others 1970 21.9
Total 9000
TOP 10 TYPES OF CANCER IN IOWA PROjECTEd FOR 2012
Cancer Deaths in Females
Type                 # of Cancers % of Total
Lung 750 25.0
Breast 410 13.6
Colon & Rectum 320 10.7
Pancreas 200 6.7
Ovary 180 6.0
Non-Hodgkin Lymphoma 120 4.0
Leukemia 110 3.7
Uterus 100 3.3
Brain 80 2.7
Multiple Myeloma 60     2.0
All Others 670 22.3
Total 3000
Cancer Deaths in Males
Type                 # of Cancers % of Total
Lung 990 29.1
Colon & Rectum 310 9.1
Prostate 300 8.8
Pancreas 200 5.9
Leukemia 150 4.4
Esophagus 140 4.1
Bladder 130 3.8
Non-Hodgkin Lymphoma 130 3.8
Kidney & Renal Pelvis 110 3.3
Brain 100 3.0
All Others 840 24.7
Total 3400
Fortunately for Iowans, the chances of being diagnosed with many types of cancer can be reduced through 
positive health practices such as smoking cessation, physical exercise, healthful dietary habits, and alcohol 
consumption in moderation. Early detection through self-examination and regular health checkups can 
improve cancer survival.
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6Lung cancer is the leading 
cause of cancer death in Iowa and 
in the U.S. In 2012 lung cancer 
will account for one out of every 
four cancer deaths. 
Between 1973 and 2009, 
47,527 males and 25,181 females 
in Iowa were diagnosed with 
lung cancer and 37,759 males 
and 18,896 females died from 
lung cancer. Among male Iowans, 
lung cancer has been the leading 
cause of cancer death for several 
decades. Among female Iowans, 
in 1991 lung cancer surpassed 
breast cancer as their leading 
cause of cancer death. Age-
adjusted rates for male lung 
cancer incidence and mortality 
in Iowa were increasing during 
the 1970s and 1980s, but have 
been declining since (Figure 
1). For females over this same 
period, these rates have been 
increasing, although less so since 
the 1990s, and are expected to 
begin decreasing during this 
decade. As a result the male 
to female ratio of lung cancer 
incidence has declined from 
4.0 to 1 during the 1970s to 1.3 
to 1 during the last decade. The 
explanation for this has been that 
cigarette smoking was common 
in men after World War I, but did 
not become common in women 
until after World War II. Cigarette 
smoking rates in men have also 
involving current and former 
heavy smokers over the age 
of 50, screened when using 
low-dose helical computed 
tomography (CT) scans versus 
routine chest X-rays, reported 
a 20% reduction in lung cancer 
mortality for those individuals 
CT screened. Routine chest 
X-rays in healthy people without 
symptoms have been shown to 
be ineffective as a screening test. 
The primary means of 
treatment for lung cancer that 
cannot be removed surgically  
has been radiation therapy  
and/or chemotherapy. This  
“one treatment fits all” approach 
is changing. Over the past few 
years, research into lung cancer 
has revealed that cancers 
LuNG CANCER
been declining for a longer period 
of time than in women.   
Lung cancer continues to be 
associated with a relatively low 
survival (Figure 2). Consequently, 
incidence and mortality rates 
mirror one another in both sexes, 
and mortality rates remain high 
relative to incidence rates (Figure 
1). Five-year relative survival 
rates for lung cancer in Iowans 
diagnosed between 1973 and 
1981 versus those diagnosed 
between 1999 and 2006 have 
increased only slightly, from 12% 
to 16% in women and from <10% 
to around 12% in men (Figure 
2). This is largely because lung 
cancer is often initially diagnosed 
only after it has spread beyond 
the lungs. A recent clinical trial 
Figure 1.  Average Annual Lung Cancer Incidence & Mortality Rates 
  in Iowa, 1973 - 2009
  (Rates expressed per 100,000 persons using 2000 US population as standard)
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7that look the same under the 
microscope can have very 
different causes at the level of 
their DNA. Furthermore, specific 
treatments targeted directly at 
the specific abnormalities of the 
DNA in individual lung cancers are 
showing promise in early clinical 
trials. As these treatments, 
tailored specifically toward the 
genetics of each cancer, are 
developed further and diffuse 
more into routine practice, and 
screening is implemented for 
heavy smokers who are most 
vulnerable to developing lung 
cancer, there is reason to hope  
for significantly improved  
survival rates for lung cancer  
in the Iowa population. 
Even with progress in  
the areas of early detection  
and therapy, it is vital that we 
continue to emphasize that lung 
cancer is largely a preventable 
disease. Risk factor reduction 
remains the primary means to 
reduce lung cancer incidence and 
mortality. For over 50 years now, 
smoking has been identified as 
the most common cause of lung 
cancer. In 2012, we project that 
Iowa will experience 2360 new 
lung cancer diagnoses. The cause 
of most of these will be smoking.
Legislation has been a 
method used by many states to 
modify tobacco use behavior.  
On March 16, 2007, Governor  
Chet Culver signed a bill that 
raised Iowa’s state excise tax on 
tobacco from $0.36 to $1.36 per 
pack. In the spring of 2008,  
Iowa lawmakers passed the 
Smokefree Air Act to protect 
employees and the general 
public. This legislation prohibited 
smoking in almost all public 
places and enclosed areas within 
places of employment, as well  
as some outdoor areas. Help for 
smokers who wanted to quit was 
provided by a dedicated Iowa 
Quitline (1-800-784-8669;  
www.quitnow.net/iowa/).  
These actions have contributed  
to an appreciable decline in the 
percent of adults who were 
current smokers by age group  
and by gender in the past decade; 
this decrease was particularly 
evident among young adults 
(Figure 3). Despite such 
successes, in 2010 Iowa still only 
ranked 20th among the states, 
with 16.1% of its adult population 
being current smokers. 
Radon is the number one 
cause of lung cancer among 
Figure 2.  Lung Cancer 5-year Relative Survival by Gender
  Iowa, 1973-2006
Figure 3.  Adults Who Were Current Smokers by Age Group 
 and Gender, Iowa 1999 vs 2010
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8individuals who have never 
smoked. Overall, radon is the 
second leading cause of lung 
cancer and is responsible for an 
estimated 21,000 lung cancer 
deaths each year in the United 
States, about 400 of which 
occur among Iowans. Radon is 
a colorless, odorless, tasteless, 
radioactive gas produced by the 
normal decay of uranium found 
in the soil. Radon typically moves 
up through the ground and 
into the air in a home through 
cracks and other openings in 
the foundation (Figure 4). Your 
home traps radon, particularly 
under closed conditions found 
when it is cold or hot outside and 
the furnace and air conditioner, 
respectively, are working. All 
99 counties in Iowa are in the 
U.S. EPA “red zone” for radon 
levels, meaning Iowans have a 
high potential for elevated radon 
levels in their homes. 
In the U.S., radon is 
measured in picocuries per liter 
(pCi/L). The EPA recommends 
indoor levels of radon remain at 
or below 4.0 pCi/L to decrease 
the risk of developing radon-
induced lung cancer. The average 
indoor radon concentration in 
Iowa is 8.5 pCi/L, more than 
6 times the national average. 
Seven out of 10 homes tested 
in Iowa have radon levels that 
exceed 4.0 pCi/L.  
The only way to find out  
if your home has an elevated 
radon concentration is to test for 
it. Do-It-Yourself radon test kits 
are available, low cost, and easy 
to perform. You can get these 
through the mail and in hardware 
and other retail stores. If radon  
is detected, the problem can be 
fixed. Radon reduction systems, 
also known as mitigation 
systems, can reduce radon levels 
in your home by up to 99 percent. 
Most systems cost between 
$1000 and $2000, depending  
on your home. Installing a 
mitigation system at the time  
of construction is ideal and  
less costly. However, systems 
Figure 4.  How Radon Enters the Home
can be installed in any type of 
home, even after construction. 
The Iowa Department of Public 
Health Radon Program website 
(http://www.idph.state.ia.us/eh/
radon.asp) provides a list of 
licensed radon mitigation 
professionals. The Iowa Radon 
Hotline (1-800-383-5992 or 
http://www.healthhouse.org) 
provides radon information to 
the public.      
9RESEARCH PROjECTS duRING 2012
The State Health Registry  
of Iowa is participating in over 
five dozen open studies approved 
by the University of Iowa Human 
Subjects Office during 2012.  
Brief descriptions of a few of 
these studies are provided.
Agricultural Health Study
The Agricultural Health 
Study (AHS) is a long-term 
study of agricultural exposures 
(including pesticides) and chronic 
disease (especially cancer)  
among commercial or private 
pesticide applicators (and their 
spouses, if married) in Iowa 
and North Carolina. The study 
is funded through the National 
Cancer Institute (NCI) and 
involves several federal agencies. 
We are in the 20th year of  
the study. 
In the first five years,  
89,658 subjects (58,564 in  
Iowa and 31,094 in North 
Carolina) were enrolled in the 
study. The total for Iowa included 
31,877 private applicators, 21,771 
spouses of private applicators, 
and 4,916 commercial applicators. 
Enrollment consisted of 
completing questionnaires about 
past exposures and health. The 
second phase of the study for 
private applicators and their 
spouses was completed at the 
end of 2003. It involved a 
telephone interview, a mailed 
dietary questionnaire, and 
collection of a cheek cell sample 
from all consenting cohort 
members. The telephone 
interview asked about pesticide 
use since enrollment, current 
farming and work practices, and 
health changes. The dietary 
health questionnaire asked about 
cooking practices and types of 
foods eaten, since cooking 
practices and diet may play a role 
in cancer and other health 
conditions. The cheek cells are 
being used to understand 
possible links between genetics, 
exposures, and disease. For 
commercial applicators, the 
second phase of the study was 
completed at the end of 2005.  
The study’s third phase began in 
2005 and ended in 2010. It 
involved updating information 
about exposures and health. 
Plans for a fourth phase of the 
study were funded and 
implemented in the fall of 2011. 
Primary activities for the Iowa 
Field Staff will be collection of 
blood and urine samples from a 
select subgroup of AHS male 
participants and collection of 
buccal cells from AHS participants 
diagnosed with cancer.      
Since 1997, cohort  
members have been linked 
annually to mortality and cancer 
registry incidence databases in 
both states. In addition, mortality 
data on the cohort are being 
obtained from the National 
Death Index. More information 
about results from this study, the 
study background, frequently 
asked questions, other resources 
(internet & telephone) for 
agricultural health information, 
references for publications 
to date, and information for 
scientific collaborators can be 
found at the website, http://
aghealth.nci.nih.gov/. The titles 
for over 150 publications from 
this study linked to PubMed are 
available at the website. The 
cancer-related references for 2011 
publications are provided in the 
last section of this report. 
Iowa Women’s Health Study
This is a population-based 
cohort of 41,837 Iowa women, 
aged 55-69, who were recruited in 
1986 to determine whether diet, 
body fat distribution and other 
risk factors are related to cancer 
incidence. Exposure and lifestyle 
information was collected in 
a baseline mailed survey and 
subsequently in several follow-
up mailed surveys. Mortality 
and cancer incidence have been 
ascertained since 1986 through 
annual linkage to the State Health 
Registry of Iowa databases and 
the National Death Index. In 2010 
the study was refunded for its 25th 
through 29th years. The project 
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has been extremely productive 
with over 225 publications, some 
of which occurred in 2011 and are 
listed in the references provided 
in the last section of this report. 
Non-Hodgkin Lymphoma (NHL) 
Case-Control Study
The State Health Registry 
of Iowa (SHRI) with other 
investigators at the Mayo Clinic 
participated in a collaborative, 
population-based case-
control study of NHL involving 
researchers at the NCI and three 
other Surveillance, Epidemiology, 
and End Results (SEER) 
registries. The main objective 
of the study was to better 
characterize risk factors for NHL. 
In Iowa, 364 live patients newly 
diagnosed with NHL between  
July 1, 1998 and June 30, 
2000 were enrolled. A similar 
number of population controls 
participated. Blood samples were 
sought from study participants. 
The SHRI also coordinated the 
acquisition of pathology reports, 
slides and tissue blocks from 
all SEER centers. The slides 
were reviewed to determine 
the reliability of NHL pathologic 
classification
More recently, we are 
collaborating with researchers 
at the Mayo Clinic to investigate 
whether genes with functional, 
common variant polymorphisms 
involved in immune function and 
regulation are associated with 
overall survival from NHL among 
these patients. To achieve this 
aim, medical record reviews 
were performed to obtain more 
detailed information on the 
treatment received for NHL. 
These research activities resulted 
in several publications during 
2011. The references for these  
are provided in the last section  
of this report. 
Patterns of Care Studies
SEER Patterns of Care 
Studies are conducted to satisfy 
a U.S. Congressional directive  
to the NCI to “assess the 
incorporation of state-of-the-art 
cancer treatment into clinical 
practice and the extent to which 
cancer patients receive such 
treatments.” This year’s Patterns 
of Care Study will involve breast, 
colorectal, and non-small cell 
lung cancers in adults diagnosed 
between January 1, 2010 and 
December 31, 2010. The 
objectives of the SEER Patterns 
of Care Study are to:  
1) describe the use of adjuvant 
therapy, which has been verified 
with the treating physician, in a 
community setting, 2) charac-
terize the practice patterns  
in different communities,  
3) describe more completely the 
use of surgery in the treatment  
of specific cancers, 4) compare 
the patterns of treatment for 
cancer over time, 5) compare 
patterns of care by age and  
race/ethnicity, 6) describe effect 
of co-morbid conditions on 
treatment, and 7) describe 
treatment by hospital 
characteristics: i.e., for profit  
vs. not for profit, teaching vs. 
non-teaching, disproportionate 
share status, etc. The SHRI  
has been involved with these 
types of studies over the  
past 20 years. Publications 
during 2011 are provided in the 
last section of this report. 
AYA Hope Study
The Adolescent and Young 
Adult (AYA) Health Outcomes and 
Patient Experience (HOPE) Study 
is another ongoing example of a 
cancer survivor study. This study 
is an initial step in addressing 
potential factors related to gaps 
in research, care and outcomes. 
From 7 SEER Registries across 
the United States, 525 patients 
(40 in Iowa), 15-39 years old at 
diagnosis between July 1, 2007 
and October 31, 2008 have been 
enrolled with any of the following 
cancers: ovarian or testicular 
cancer, Hodgkin lymphoma, 
non-Hodgkin lymphoma, acute 
lymphoblastic leukemia, or 
selected types of sarcoma. 
Those who responded were 
11
representative of all AYA cancer 
survivors during this time period. 
91% of the 525 have completed 
a subsequent survey 8 to 17 
months after the initial survey 
to obtain additional follow-up 
information regarding their 
cancer survivorship experience. 
During 2011, the first manuscript 
describing this study was 
published (see last section 
for listing) with several more 
reports forthcoming regarding 
factors related to access to care, 
treatment and follow-up care, 
and impact of cancer on physical 
and psychosocial functioning. 
Studies Involving Tissue
Today, researchers are 
increasingly looking to obtain 
tissue to study molecular 
characteristics of cancers. 
Several studies that involve the 
SHRI have complemented their 
subject data with tissue including 
the Iowa Women’s Health Study 
and the NHL Case-Control Study. 
In addition, the SHRI is currently 
involved with several other 
studies that involve tissue. One 
of these involves pre-invasive 
breast cancer and is led by an 
investigator at Johns Hopkins 
University. The primary objective 
of this project is to identify tissue 
biomarkers of pre-invasive 
breast cancer that are associated 
with progression to invasive 
breast cancer and are detectable 
at the time of diagnosis. Such 
information would be very helpful 
to health care providers in the 
clinical management of these 
patients. The goal for the SHRI 
is to provide tissue for over 100 
case patients and their matched 
controls. During 2011, several 
articles involving tissue from 
Iowans were published, the 
references for which are provided 
in the last section of this report.     
The WECARE Study
The WECARE (Women’s 
Environmental Cancer and 
Radiation Epidemiology) Study 
is an example of a second cancer 
study. This study is designed 
to examine gene carrier status, 
demographic and lifestyle factors 
as well as environmental and 
treatment factors reported to be 
associated with an initial breast 
cancer as they relate to the 
development of a second breast 
cancer in the opposite breast. 
Eligible cases were diagnosed 
with a first breast cancer between 
1985 and 2008 that did not 
spread beyond the regional lymph 
nodes at diagnosis and a second 
primary contralateral breast 
cancer diagnosed at least one 
year after the first breast cancer 
diagnosis. Eligible controls were 
women with unilateral breast 
cancer who were individually 
matched to cases on year of birth, 
year of diagnosis, registry region, 
and race. The controls must have 
survived without any subsequent 
diagnosis of cancer and with an 
intact contralateral breast during 
the interval that elapsed between 
their matched case’s first and 
second breast cancer diagnoses. 
Data collection not only involved 
medical record review, but 
also participant interviews and 
biosample collection, either 
cheek cells or blood. Currently, 
we are recruiting more eligible 
participants to a second phase 
of this study to enable a genome-
wide association study to be 
conducted to learn more about 
how genetic, environmental, and 
lifestyle factors work together 
to influence whether a woman 
with breast cancer will develop 
a second breast cancer in the 
opposite breast. A listing of 
publications from the WECARE 
Study during 2011 are provided in 
the last section of this report.
Transplant Cancer Match Study
Solid organ transplantation 
provides life-saving treatment 
for end-stage organ disease but 
is associated with substantially 
elevated cancer risk, largely due 
to the need to maintain long-term 
immunosuppression. Important 
questions remain concerning 
the role of immunosuppression 
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SEER-Medicare
In the early 1990s, the 
cancer incidence and survival 
data from the SHRI was 
combined with other SEER 
Registry data and linked to 
Medicare data. This linked  
data set has been updated on 
several occasions since and has 
become an important data 
resource for cancer research 
involving epidemiologic and 
and other factors in causing 
cancer in this setting. Staff 
at two federal agencies, the 
NCI and the Health Resources 
and Services Administration 
(HRSA), are creating a database 
through linkage of information 
on U.S. transplant recipients 
(383,444 transplant recipients 
during 1987-2007), wait list 
candidates (216,067 candidates 
during 1987-2007 in addition to 
those who were subsequently 
transplanted), and donors 
(61,430 deceased donors, 
57,961 living donors during 
1999-2007) with information 
on cancer from multiple U.S. 
cancer registries, including the 
State Health Registry of Iowa. 
These data are being used to 
conduct research concerning 
the spectrum of cancer risk in 
transplant recipients. The data 
will also be used by HRSA in its 
public health role overseeing 
the U.S. solid organ transplant 
network to maintain and improve 
safety of organ transplantation, 
and will allow NCI to better 
characterize the burden of cancer 
in this population and discover 
risk factors for cancer among 
immunosuppressed individuals.
Cooperative Agreements and Other Registries
In the Midwest, the SHRI maintains cooperative agreements 
with several hospital cancer registries and other agencies/entities. 
Some of the latter include:
• Iowa Department of Public Health
• Iowa Cancer Consortium 
• The University of Iowa
 • Center for Health Effects of Environmental Contamination
 • Center for Public Health Statistics
 • Environmental Health Sciences Research Center
 • Health Effectiveness Research Center
 • Holden Comprehensive Cancer Center
 • Iowa Center for Agricultural Safety and Health
 • Injury Prevention Research Center
 • Preventive Intervention Center 
 • Reproductive Molecular Epidemiology Research  
      & Education Program
 
health services research  
related to the diagnosis and 
treatment procedures, costs,  
and survival of cancer patients.  
Over the years many publications 
have resulted from this linked 
data set including several  
during 2011, which are listed at 
http://healthservices.cancer.gov/
seermedicare/overview/
publications.html. 
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